Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (HK:9989)
:9989
Want to see HK:9989 full AI Analyst Report?
9989 Stock Chart & Stats
HK$5.19
HK$0.02(0.54%)
At close: 4:00 PM EST
HK$5.19
HK$0.02(0.54%)
Day’s Range― - ―
52-Week RangeHK$4.38 - HK$7.26
Previous CloseN/A
Volume172.00K
Average Volume (3M)1.16M
Market Cap
HK$16.60B
Enterprise ValueHK$14.56B
Total Cash (Recent Filing)HK$3.50B
Total Debt (Recent Filing)HK$2.79B
Price to Earnings (P/E)8.4
Beta0.92
Next Earnings
Aug 31, 2026EPS Estimate
0.13Next Dividend Ex-DateN/A
Dividend Yield5.23%
Share Statistics
EPS (TTM)0.26
Shares Outstanding220,094,500
10 Day Avg. Volume947,650
30 Day Avg. Volume1,161,300
Financial Highlights & Ratios
PEG Ratio-0.43
Price to Book (P/B)0.57
Price to Sales (P/S)1.25
P/FCF Ratio4.31
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)0.54
Revenue Forecast (FY)HK$6.73B
Bulls Say, Bears Say
Bulls Say
Free Cash Flow QualitySustained free cash flow that closely tracks net income indicates high earnings quality and strong cash conversion. Over a 2–6 month horizon this supports dividend capacity, debt servicing, and reinvestment in R&D or capacity, giving the company financial flexibility through cycles.
Conservative LeverageLow leverage provides balance-sheet resilience and strategic optionality. With debt well below earlier peaks the company can fund capex, regulatory compliance, or M&A without stressing liquidity, reducing refinancing risk and supporting long-term operational continuity.
Niche API & CDMO FocusSpecialization in heparin APIs plus contract development/manufacturing services creates durable barriers: complex manufacturing, regulatory approvals and long-term supply relationships. This niche mix supports stable revenue streams and higher switching costs for customers over time.
Bears Say
Flat Revenue GrowthStagnant top-line growth limits the firm's ability to scale fixed-cost recovery and improve margins. Without clear secular revenue expansion, profitability gains must come from cost cuts or mix shift, increasing execution risk and constraining longer-term return improvement.
Inconsistent Cash/Earnings HistoryPast volatility in operating and free cash flow signals cyclical or execution vulnerabilities. Even with current strong conversion, uneven historical performance raises the risk that cash generation may deteriorate under pressure, complicating capital planning and dividend sustainability.
Low Return On EquityLow ROE indicates the balance sheet is not translating into strong shareholder returns. Over months this suggests limited profit reinvestment effectiveness or margin constraints, reducing capacity to generate high returns from future growth or capital allocation initiatives.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H News
9989 FAQ
What was Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s price range in the past 12 months?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H lowest stock price was HK$4.38 and its highest was HK$7.26 in the past 12 months.
What is Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s market cap?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s market cap is HK$16.60B.
When is Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s upcoming earnings report date?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s upcoming earnings report date is Aug 31, 2026 which is in 118 days.
How were Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s earnings last quarter?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H released its earnings results on Apr 29, 2026. The company reported HK$0.147 earnings per share for the quarter, beating the consensus estimate of HK$0.126 by HK$0.021.
Is Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H overvalued?
According to Wall Street analysts Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s price is currently Overvalued.
Does Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H pay dividends?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H pays a Annually dividend of HK$0.272 which represents an annual dividend yield of 5.23%. See more information on Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H dividends here
What is Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s EPS estimate?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s EPS estimate is 0.13.
How many shares outstanding does Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H have?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H has 220,094,500 shares outstanding.
What happened to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H’s price movement after its last earnings report?
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H reported an EPS of HK$0.147 in its last earnings report, beating expectations of HK$0.126. Following the earnings report the stock price went down -0.207%.
Which hedge fund is a major shareholder of Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H?
Currently, no hedge funds are holding shares in HK:9989
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
37.12%
12-Months-Change
Fundamentals
Return on Equity
2.86%
Trailing 12-Months
Asset Growth
0.52%
Trailing 12-Months
Company Description
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. engages in the manufacture and sale of pharmaceutical products in Hong Kong, the United States, Europe, Mainland China, and internationally. The company operates through four segments: Finished dose pharmaceutical products, Active Pharmaceutical Ingredients (API), Contract Development and Manufacturing Organization, and Others. Its pharmaceutical products consist of finished dose pharmaceutical products, which primarily include enoxaparin sodium injection; API products, including heparin sodium API and enoxaparin sodium API; and other products, such as pancreatin API. The company is also involved in the provision of research and development, manufacturing, quality management, and program management services; and development and manufacture of recombinant pharmaceutical products, critical non-viral vectors, intermediates for gene therapy, and naturally derived pharmaceutical products. In addition, it engages in property management, investment management and consulting, biopharmaceutical technology development and consulting, and equity and venture investment activities; research, development, and production of biopharmaceuticals; production and sale of heparin sodium; provision of services on pharmaceutical related activities; and trading of medical and biopharmaceutical products. The company was formerly known as Shenzhen Hepalink Pharmaceutical Co.,Ltd. and changed its name to Shenzhen Hepalink Pharmaceutical Group Co., Ltd. in February 2017. Shenzhen Hepalink Pharmaceutical Group Co., Ltd. was founded in 1998 and is headquartered in Shenzhen, the People's Republic of China.
Shenzhen Hepalink Pharmaceutical Group Co., Ltd. Class H (9989) Earnings & Revenues
Technical Analysis
HUTCHMED (China)
―
Shanghai Fosun Pharmaceutical (Group) Co
―
China Resources Pharmaceutical Group Ltd.
―
―
CanSino Biologics, Inc. Class H
―
Options Prices
Currently, No data available
---